Terms ending in 2041
Every in-force patent on Genentech, Inc.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,273,072 | Suprachoroidal Injection Device In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 12,139,496 | Therapeutic Compounds and Methods of Use Thereof In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 12,115,015 | Deep Convolutional Neural Networks for Tumor Segmentation with Positron Emission Tomography In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | |
| US 12,098,365 | Modified Mammalian Cells In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 11,999,787 | TIE2-BINDING Agents and Methods of Use In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 11,919,948 | Isoform-Selective Anti-Tgf-Beta Antibodies and Methods of Use In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 12,740,983 | CDK Inhibitors In force · Low confidence | Genentech, Inc. | In force | Low confidence | |
| US 12,740,984 | CDK Inhibitors In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | |
| US 12,751,951 | CDK Inhibitors In force · Low confidence | Genentech, Inc. | In force | Low confidence | |
| US 12,303,495 | Treatment of Breast Cancer Using Combination Therapies Comprising GDC-9545 and a CDK4/6 Inhibitor In force · High confidence | Genentech, Inc. | In force | High confidence | |
| 38 more term ends in 2041 · Pro | |||||
10 of 48 patents shown. Soonest term end first, then patent number.
Pro members see all 48.
44 of these are in force and held by Genentech, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.